title: Comment on Beltrand et al. Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. Diabetes Care 2015;38:2033-2041.
authors.affiliation: UMR 8199-European Genomic Institute for Diabetes, University of Lille, Lille, France CNRS UMR 8199, Lille, France Institut Pasteur de Lille, Lille, France martine.vaxillaire@cnrs.fr.
authors.forename: Martine
authors.initials: M
authors.lastname: Vaxillaire
authors.affiliation: UMR 8199-European Genomic Institute for Diabetes, University of Lille, Lille, France CNRS UMR 8199, Lille, France Institut Pasteur de Lille, Lille, France.
authors.forename: Amélie
authors.initials: A
authors.lastname: Bonnefond
authors.affiliation: UMR 8199-European Genomic Institute for Diabetes, University of Lille, Lille, France CNRS UMR 8199, Lille, France Institut Pasteur de Lille, Lille, France Department of Endocrinology, Diabetology and Metabolism, Centre Hospitalier Régional Universitaire de Lille, Lille, France Department of Genomics of Common Disease, School of Public Health and Hammersmith Hospital, Imperial College London, London, U.K.
authors.forename: Philippe
authors.initials: P
authors.lastname: Froguel
mesh_terms: D003920:Diabetes Mellitus; D006801:Humans; D009154:Mutation; D015221:Potassium Channels / Q000235:genetics*; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics; D013453:Sulfonylurea Compounds
chemical_list: D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D013453:Sulfonylurea Compounds